Tuesday, May 07, 2013 8:35:24 PM
If they had $4 million in revenues and a market cap of $25 million then that means it is trading at a little over 6 times revenues.
6 X $4 million revenues = $24 million market cap.
The large caps trade at between 2 to 3 times revenues but it's not fair to compare them to a company of this size.
The revenues themselves do not factor in what a market cap trades at though, only the shares outstanding and the share price do that.
how would the PPS change should the company put out an Abuse Resistant product that captures say $100 million dollars a year???
So if we had an additional $100 million in revenues and the company traded about the same prices to revenues that would mean a market cap of about $400 million dollars.
To get the share price you have to take the market cap and divide by the shares outstanding, say 400 million.
That means a share price of one dollar per share.
Added: I can't PM as i have the cheapie account, but yes the revenues do not directly affect market cap of companies. They do indirectly as traders buy and sell based on various factors including revenues. However companies have gone bankrupt with high revenues which shows that revenues alone don't mean much unless you have profitability at some point to go along with the revenues. Of coarse you can be cash flow positive and still lose money in the accounting department and stay in business, some businesses trade on cash flow for that reason.
This company going to cash flow positive is a good sign and is why they are moving in that direction now and why some like it, as it stops the bleeding of cash at least on the generic portion. If Lodrane ever was approved again, at least the ones that were pulled that was $4 million a year they lost that would slowly come back.
As some have said there is a lot that could happen to get the market cap higher here. For comparison ACUR trades at a market cap of about $100 million, but they also have approved abuse resistant products.
6 X $4 million revenues = $24 million market cap.
The large caps trade at between 2 to 3 times revenues but it's not fair to compare them to a company of this size.
The revenues themselves do not factor in what a market cap trades at though, only the shares outstanding and the share price do that.
how would the PPS change should the company put out an Abuse Resistant product that captures say $100 million dollars a year???
So if we had an additional $100 million in revenues and the company traded about the same prices to revenues that would mean a market cap of about $400 million dollars.
To get the share price you have to take the market cap and divide by the shares outstanding, say 400 million.
That means a share price of one dollar per share.
Added: I can't PM as i have the cheapie account, but yes the revenues do not directly affect market cap of companies. They do indirectly as traders buy and sell based on various factors including revenues. However companies have gone bankrupt with high revenues which shows that revenues alone don't mean much unless you have profitability at some point to go along with the revenues. Of coarse you can be cash flow positive and still lose money in the accounting department and stay in business, some businesses trade on cash flow for that reason.
This company going to cash flow positive is a good sign and is why they are moving in that direction now and why some like it, as it stops the bleeding of cash at least on the generic portion. If Lodrane ever was approved again, at least the ones that were pulled that was $4 million a year they lost that would slowly come back.
As some have said there is a lot that could happen to get the market cap higher here. For comparison ACUR trades at a market cap of about $100 million, but they also have approved abuse resistant products.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
